OUTLOOK THERAPEUTICS, INC.

Analyst Reco. Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
7.58 ^USD	-1.94%		-11.86%	-3.81%

15/04	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI
15/04	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	27/03	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	15/02	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	15/02	MT
Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2	25/01	MT
Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57	25/01	MT
Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target	27/12	MT
Chardan Downgrades Outlook Therapeutics to Neutral From Buy	31/23/31	MT
HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1	31/23/31	MT
Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy	30/23/30	MT
Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50	30/23/30	MT
BTIG Downgrades Outlook Therapeutics to Neutral From Buy	30/23/30	MT
Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target	13/23/13	MT
Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target	03/23/03	MT
Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target	06/23/06	MT
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating	06/23/06	MT
BTIG Starts Outlook Therapeutics at Buy With $7 Price Target	31/22/31	MT
Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target	13/22/13	MT
Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating	27/21/27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW